Doripenem

DORIPIK (Doripenem) is a broad-spectrum, carbapenem antibiotic. It was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. Doripenem is a broad-spectrum carbapenem antibiotic with activity against many gram-positive and gram-negative aerobic bacteria, as well as a variety of anaerobes. Doripenem is different from most beta-lactams due to its stability against hydrolysis by most beta-lactamases, including penicillinases, cephalosporinases, ESBL, and Amp-C producing enterobacteriaceae. Doripenem is used in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, caused by designated susceptible bacteria.

Therapy Area: Antibiotic (Injectables)
Form: Parentral intravenous injection
Packaging: 1x1 vial

COMPOSITION:

Doripenem 500mg

MODE OF ACTION:

Doripenem’s bactericidal mechanism of action is mostly due to cell death after inhibition of bacterial enzymes called penicillin-bindng proteins (PBPs), which are responsible for peptidoglycan cross-linking during the synthesis of the bacterial cell wall. Carbapenems mainly have high affinity for PBPs 1a, 1b, 2 and 3. Inhibition of each PBP usually results in a different inactivating mechanism. Inhibition of PBPs 1a and 1b results in fast bacterial killing through the formation of spheroplasts, inhibition of PBP 2 results in rod-shaped bacteria to become spherical, and inhibition of PBP 3 results in filamentous-shaped organisms. The PBPs preferentially bound by different carbapenems depend on the organism. In E.coli and P.aeruginosa, doripenem binds to PBP 2, which is involved in the maintenance of cell shape, as well as to PBPs 3 and 4. Doripenem has a 1-beta-methyl side chain, which allows it to be relatively resistant to dehydropeptidase, as well as a trans-alpha-1-hydroxyethyl group at position 6 which provides beta-lactamase resistance. Like other carbapenems, doripenem is different from most beta-lactams due to its stability against hydrolysis by most beta-lactamases, including penicillinases, cephalosporinases, ESBL, and Amp-C producing enterobacteriaceae.

INDICATIONS

  • Complicated IAI
  • Nosocomial Pneumonia
  • Complicated UTI

Dosage

500mg IV infusion every 8 hours upto 5-14 days depending severity of infection

Disclaimer:

This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About DORIPIK

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.